Komori
Other Disclosures4880CellSource Co.,Ltd.Pharmaceuticals

The Knee Trouble Relief Committee is now under way. The new normal in knee treatment has already begun.

CellSource launched an awareness project in collaboration with medical institutions and healthcare professionals to inform the public about knee health and regenerative medicine options, and released a dedicated website and documentary videos featuring patients and physicians.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Knee Concerns Trisaru CommitteeAwareness websitePatient and physician documentary videosRegenerative medicine and related treatments, including PRP therapy, PFC-FD™ therapy, and treatments using adipose-derived stem cells
Applicable field (uses covered by this announcement)

Knee health awareness, orthopedics, and information on treatment options including regenerative medicine

Launch date23 June 2026 (awareness website launch, actual)
What the company reported numerically
Quantitative Effects

74.4% of people with knee problems have not sought medical attention; 84.6% dislike the idea of causing their families the burden of providing care; and 39.3% consider mobility the ability they most want to maintain.

Usage history

As part of the company’s contract processing track record, more than 2,100 medical institutions nationwide and more than 130,000 cases in total.

Relationship between the counterparty and the company
CellSource Co.,Ltd.4880
Relationship with the Company

The company serves as the project secretariat and conducts awareness activities in collaboration with medical institutions and healthcare professionals.

Registration number and expiry date

Facility number for an authorized facility manufacturing specified cell-processed products: FA3240004; expiry date: Not disclosed

Location (as indicated in this announcement)

Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredKnee Concerns Trisaru Committee, Awareness website, Patient and physician documentary videos, Regenerative medicine and related treatments, including PRP therapy, PFC-FD™ therapy, and treatments using adipose-derived stem cells
Relationship with the CompanyThe company serves as the project secretariat and conducts awareness activities in collaboration with medical institutions and healthcare professionals.
Launch date23 June 2026 (awareness website launch, actual)
Applicable areaKnee health awareness, orthopedics, and information on treatment options including regenerative medicine
Registration number and expiry dateFacility number for an authorized facility manufacturing specified cell-processed products: FA3240004; expiry date: Not disclosed
LocationShibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo
Quantitative Effects74.4% of people with knee problems have not sought medical attention; 84.6% dislike the idea of causing their families the burden of providing care; and 39.3% consider mobility the ability they most want to maintain.
Usage historyAs part of the company’s contract processing track record, more than 2,100 medical institutions nationwide and more than 130,000 cases in total.
Items this document does not state (10)
CounterpartyCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyLocation scaleImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To bridge the gap between the large number of people who have not sought medical attention despite experiencing knee problems and the lack of sufficient public awareness of options such as regenerative medicine.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
The Knee Trouble Relief Committee is now under way. The new normal in knee treatment has already begun. | CellSource Co.,Ltd. (4880) timely disclosure | Komori